Multiple myeloma gammopathies

Preclinical assessment of an antibody–PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1
Fig. 2

References

  1. 1.

    Huff CA, Matsui W. Multiple myeloma cancer stem cells. J Clin Oncol. 2008;26:2895–900.

    Article  Google Scholar 

  2. 2.

    Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–11.

    CAS  Article  Google Scholar 

  3. 3.

    Leung-Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, Reece DE, et al. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell. 2013;24:289–304.

    CAS  Article  Google Scholar 

  4. 4.

    Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, et al. Characterization of clonogenic multiple myeloma cells. Blood. 2004;103:2332–6.

    CAS  Article  Google Scholar 

  5. 5.

    Pilarski LM, Belch AR. Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 (+) hematopoietic progenitors. Clin Cancer Res. 2002;8:3198–204.

    PubMed  Google Scholar 

  6. 6.

    Reghunathan R, Bi C, Liu SC, Loong KT, Chung TH, Huang G, et al. Clonogenic multiple myeloma cells have shared stemness signature associated with patient survival. Oncotarget. 2013;4:1230–40.

    Article  Google Scholar 

  7. 7.

    Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013;19:2048–60.

    CAS  Article  Google Scholar 

  8. 8.

    Tai YT, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123:3128–38.

    CAS  Article  Google Scholar 

  9. 9.

    de Mel S, Lim SH, Tung ML, Chng WJ. Implications of heterogeneity in multiple myeloma. Biomed Res Int. 2014;2014:232546.

    PubMed  PubMed Central  Google Scholar 

  10. 10.

    Chang H, Samiee S, Yi QL. Prognostic relevance of CD56 expression in multiple myeloma: a study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant. Leuk Lymphoma. 2006;47:43–7.

    CAS  Article  Google Scholar 

  11. 11.

    Kerk SA, Finkel KA, Pearson AT, Warner KA, Zhang Z, Nor F, et al. 5T4-targeted therapy ablates cancer stem cells and prevents recurrence of head and neck squamous cell carcinoma. Clin Cancer Res. 2017;23:2516–27.

    CAS  Article  Google Scholar 

  12. 12.

    Tiberghien AC, Levy JN, Masterson LA, Patel NV, Adams LR, Corbett S, et al. Design and synthesis of tesirine, a clinical antibody-drug conjugate pyrrolobenzodiazepine dimer payload. ACS Med Chem Lett. 2016;7:983–7.

    CAS  Article  Google Scholar 

  13. 13.

    Harper J, Lloyd C, Dimasi N, Toader D, Marwood R, Lewis L, et al. Preclinical evaluation of MEDI0641, a pyrrolobenzodiazepine-conjugated antibody-drug conjugate targeting 5T4. Mol Cancer Ther. 2017;16:1576–87.

    CAS  Article  Google Scholar 

  14. 14.

    Sanchez E, Li M, Kitto A, Li J, Wang CS, Kirk DT, et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol. 2012;158:727–38.

    CAS  Article  Google Scholar 

  15. 15.

    Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J. Curing myeloma at last: defining criteria and providing the evidence. Blood. 2014;124:3043–51.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

We gratefully acknowledge Jeff Carrell (MedImmune) for his assistance with flow cytometry; Terrence O’Day (MedImmune) for statistical support; Deborah Shuman (MedImmune) for editorial assistance during the preparation of this manuscript; and Sepi Farshadi (MedImmune) for help with the preparation of figures. This study was funded by MedImmune, the global biologics R&D arm of AstraZeneca.

Author contributions

KK, EMH, SBT, MF and ND designed experiments, analyzed and interpreted data, and wrote the manuscript; KK, JM, RV, SB, SBT, MF, PGH, RF, BB, CC, LW, RC and Y-TT designed and performed experiments and interpreted data; XX and HZ designed experiments and interpreted data; KCA, RH, PWH and DAT provided guidance, intellectual input, and reviewed the paper; all authors participated in critical review and editing of the manuscript.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Krista Kinneer.

Ethics declarations

Conflict of interest

Y-TT declares that she has no conflict of interest. KCA is the scientific founder of Oncopep and C4 Therapeutics and serves on the advisory boards of MedImmune, Bristol-Myers Squibb, Gilead and Millenium Pharmaceuticals. PWH is an employee of Spirogen and has stock and/or stock interests in AstraZeneca. All other authors are employees of MedImmune or were employees of MedImmune while they were involved with this work and have stock and/or stock interests in AstraZeneca.

Electronic supplementary material

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kinneer, K., Flynn, M., Thomas, S.B. et al. Preclinical assessment of an antibody–PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells. Leukemia 33, 766–771 (2019). https://doi.org/10.1038/s41375-018-0278-7

Download citation

Further reading

Search

Quick links